Ads
related to: scopolamine 1.5 patch discontinued products
Search results
Results From The WOW.Com Content Network
Scopolamine, also known as hyoscine, [9] or Devil's Breath, [10] is a natural or synthetically produced tropane alkaloid and anticholinergic drug that is used as a medication to treat motion sickness [11] and postoperative nausea and vomiting.
The patch is labelled with the time and date of administration as well as the administrator's initials. Microneedle patch size comparison [1] A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. An advantage of a transdermal drug delivery ...
Scopolamine (Hyoscine) has anti-emetic activity and is, therefore, used to treat motion sickness. Antimuscarinics are also used as anti-parkinsonian drugs. In parkinsonism , there is imbalance between levels of acetylcholine and dopamine in the brain, involving both increased levels of acetylcholine and degeneration of dopaminergic pathways ...
The transdermal patch form is also known as the "selegiline transdermal system" or "STS" and is applied once daily. [9] [12] [27] [65] [8] They are 20, 30, or 40 cm 2 in size and contain a total of 20, 30, or 40 mg selegiline per patch (so 20 mg/20 cm 2, 30 mg/30 cm 2, and 40 mg/40 cm 2), respectively.
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. [5] It is prescribed for nausea and vomiting due to motion sickness [6] or other sources such as chemotherapy, [7] vertigo, [8] or Ménière's disease. [9]
Some common side effects such as drowsiness, dry mouth, and tiredness may occur. Meclizine has been shown to have fewer dry mouth side effects than the traditional treatment for motion sickness, transdermal scopolamine. [16] A very serious allergic reaction to this drug is unlikely, but immediate medical attention should be sought if it occurs.
[32] [33] [9] The purpose of this was to absorb the primary and transdermally-active alkaloid scopolamine through the skin, thus eliminating the risk of the additional toxicity from atropine and hyoscyamine that is inevitably present with oral ingestion of the plant but not when used topically.
Ligands targeting the mAChR that are currently approved for clinical use include non-selective antagonists for the treatment of Parkinson's disease, [34] atropine (to dilate the pupil), scopolamine (used to prevent motion sickness), and ipratropium (used in the treatment of COPD). [4] [35]